Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week . (4th August 2022)

• Record Type: Journal Article
• Authors: De Caterina, Raffaele; Agewall, Stefan; Andreotti, Felicita; Angiolillo, Dominick J; Bhatt, Deepak L; Byrne, Robert A; Collet, Jean-Philippe; Eikelboom, John; Fanaroff, Alexander C; Gibson, C Michael; Goette, Andreas; Hindricks, Gerhard; Lip, Gregory Y H; Potpara, Tatjana; Thiele, Holger; Lopes, Renato D; Galli, Mattia
• Is Part Of: European heart journal. Volume 43:Number 37(2022)
• Page Start: 3512
• Page End: 3527
• Publication Date: 2022-08-04
• Subjects: Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehac294
• Languages: English
• ISSNs: 0195-668X

Abstract

Graphical Abstract: Graphical abstract Key points in favour or against the use of one-week triple antithrombotic therapy for the majority of patients with AF and ACS/PCI. Abbreviations: TT, triple antithrombotic therapy; OAC, oral anticoagulant; DAPT, dual antiplatelet therapy; RCT, randomised controlled trials; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.